News

Filter

Current filters:

EliquisAnti-viralsJanssen

1 to 9 of 96293 results

ESMO 2014: Eisai’s lenvatinib could revolutionize treatment of rare thyroid cancer

ESMO 2014: Eisai’s lenvatinib could revolutionize treatment of rare thyroid cancer

30-09-2014

An orphan drug could offer real hope to patients with rare thyroid cancer, Japanese drugmaker Eisai revealed…

EisaiInterviewsJapanlenvatinibOncologyPharmaceuticalResearch

Johnson & Johnson to acquire Alios BioPharma

Johnson & Johnson to acquire Alios BioPharma

30-09-2014

US health care giant Johnson & Johnson has signed a definitive agreement to acquire Alios BioPharma,…

AL-8176Alios BioPharmaAnti-viralsJohnson & JohnsonMergers & AcquisitionsPharmaceuticalUSA

Indian government takes action over dubious fixed-dose combinations

30-09-2014

In a bid to weed out potentially unsafe combinations, the Central Drugs Standards and Control Organization…

GenericsIndiaPricingRegulation

Pfizer and Kyowa Hakko collaborate on immuno-oncology combination study

30-09-2014

US pharma major Pfizer and Japanese drugmaker Kyowa Hakko Kirin have entered into an agreement to explore…

ImmunologicalsKyowa Hakko KirinmogamulizumabOncologyPF-05082566PfizerPharmaceuticalResearch

ESMO 2014: Takeda and Seattle Genetics' Adcetris, Merck's Keytruda and B-MS' Opdivo

ESMO 2014: Takeda and Seattle Genetics' Adcetris, Merck's Keytruda and B-MS' Opdivo

30-09-2014

Seattle Genetics and Japan’s largest drugmaker Takeda Pharmaceutical have reported positive results…

AdcetrisBiotechnologyBristol-Myers SquibbKeytrudaMerck & CoMerck Research LaboratoriesOncologyOpdivoResearchSeattle GeneticsSpainTakeda Pharmaceuticals

Merck's entry into allergic rhinitis market will send total market value soaring by 2018, says GlobalData

Merck's entry into allergic rhinitis market will send total market value soaring by 2018, says GlobalData

30-09-2014

The US market for treatments of allergic rhinitis is set to see its value increase fourfold by 2018,…

GlobalDataGrastekMarkets & MarketingMerck & CoOralairPharmaceuticalRagwitekRespiratory and PulmonarySingulairUSA

Avacta Life Sciences invests $16.2 million in Affimers as engineered alternative to antibodies

Avacta Life Sciences invests $16.2 million in Affimers as engineered alternative to antibodies

30-09-2014

Avacta Life Sciences, a division of Avacta Group is investing £10 million ($16.2 million) in the launch…

AvactaBiotechnologyResearchUK

UCB launches awareness campaign for non-motor symptoms of Parkinson's disease

UCB launches awareness campaign for non-motor symptoms of Parkinson's disease

30-09-2014

Belgian drugmaker UCB has launched an awareness-raising campaign around brain-related illnesses such…

EuropeNeurologicalPharmaceuticalSocial IssuesUCB

1 to 9 of 96293 results

Back to top